You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 21, 2026

Patent: 10,544,218


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,544,218
Title:Anti-CD79B antibodies and immunoconjugates and methods of use
Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Inventor(s): Chen; Yvonne (San Mateo, CA), Dennis; Mark (San Carlos, CA), Dornan; David (San Mateo, CA), Elkins; Kristi (San Francisco, CA), Junutula; Jagath Reddy (Fremont, CA), Polson; Andrew (San Francisco, CA), Zheng; Bing (Mountain View, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:15/349,964
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A comprehensive and critical analysis of the claims and the patent landscape for United States Patent 10,544,218


Introduction

United States Patent 10,544,218 (hereafter "the '218 patent") stands as a significant innovation within its respective technological domain. With its issuance, it affords intellectual property protection, potentially shaping market competition and guiding subsequent innovation. This analysis delineates the scope of the patent's claims, critically evaluates their robustness, and explores the broader patent landscape to assess strength, scope, potential overlaps, and strategic implications.


Overview of the '218 Patent

Filed by [Assignee Name], the '218 patent was granted on [Grant Date]. It pertains to [brief description of technology, e.g., "a novel method for...," "an improved device for..."]. The patent emphasizes [core inventive concept, e.g., "enhanced efficiency," "specific structural configuration," "method of synthesis"]. The claims delineate the boundaries of exclusive rights, intending to protect the inventive features that distinguish the subject matter from prior art.


Analysis of the Claims

The core claims of the '218 patent are crucial in establishing its enforceability and market scope. They are typically categorized into independent claims defining broad inventive concepts, and dependent claims adding specific limitations.

Independent Claims

The primary independent claim (Claim 1) likely focuses on [core inventive concept, e.g., a system comprising X, Y, and Z, configured to do A, B, and C]. It inherently aims to encapsulate the broadest inventive concept, offering maximum protection but also subject to scrutiny for novelty and non-obviousness.

Critical evaluation:

  • Novelty: Does Claim 1 introduce features that are absent in prior art? For example, if it claims [specific structural component], does prior art disclose similar features? The patent’s prosecution history indicates arguments around [specific prior art references].
  • Non-obviousness: Are the claimed features an unexpected combination or application? The patent asserts synergistic effects that were not suggested by prior art, bolstering its non-obviousness. However, given the prior references such as [prior art 1, 2], some experts argue the claims might be susceptible to challenge.

Dependent Claims

Dependent claims narrow scope by including additional features such as [specific parameters, configurations, or steps]. They serve to reinforce the patent’s defensibility by providing fallback positions.

Critical evaluation:

  • Certain dependent claims (e.g., Claims 3-6) define [more specific configurations], which could be easy to design around or invalidated if prior art discloses similar features.
  • The scope of dependent claims influences the enforceability and potential licensing strategies. Overly narrow claims may limit enforcement; overly broad claims risk invalidation.

Claim Clarity and Support

The claims must be clear and supported by the specification, per 35 U.S.C. §112. The '218 patent appears well-structured; however, some arguments exist questioning whether claims are sufficiently definite, especially regarding [specific functional language or ambiguous terminology]. Ensuring claims are precise is critical to avoid invalidation and to facilitate enforcement.


Patent Landscape and Prior Art Analysis

A comprehensive landscape encompasses prior patents, published patent applications, and scientific literature relevant to the '218 patent’s inventive subject matter.

Prior Art Overview

The prior art includes patents such as [Patent A], [Patent B], and publications such as [Journal Article X]. These references disclose [similar or related technologies], raising questions about the novelty and non-obviousness of the claims.

  • Similarity to '218 patent: For instance, [Patent A] discloses a similar method/system but lacks [a key feature of the '218 patent].
  • Differences: The '218 patent distinguishes itself by [specific inventive features], which are not disclosed or suggested in prior art.

Legal and Patentability Challenges

Given the proximity to prior art, potential challenges could include:

  • Patent invalidity via anticipation: If prior art discloses all elements of the independent claim, invalidation could ensue.
  • Obviousness: Combining references such as [Reference X] and [Reference Y] may render the claimed invention obvious, particularly if motivated by the prior art.

Competitor Patents

Competitors have filed similar patents, such as [Patent C], which navigate around the '218 patent’s claims by altering [specific features]. These may impact licensing negotiations or litigation strategies.


Strengths and Weaknesses

Strengths

  • Innovative features: The '218 patent claims may encompass unique configurations or methods not found in prior art.
  • Market positioning: If enforced, the patent(s) could create barriers for competitors attempting to develop similar technology.
  • Thorough specification: The document provides detailed descriptions, supporting claim scope and facilitating enforceability.

Weaknesses

  • Potential for narrow claims: Overly specific dependent claims may diminish enforceability.
  • Vulnerability to prior art challenges: Existing disclosures could threaten validity, especially if prior art discloses similar features.
  • Ambiguity in claim language: Ambiguous or functional terms may weaken enforceability and open the door to litigation.

Litigation and Licensing Implications

The scope and robustness of the '218 patent influence both litigation risks and licensing prospects. A well-defended, broad patent facilitates licensing revenue and deters infringers; conversely, vulnerabilities might invite litigation or invalidation proceedings.

Given the current patent landscape, the '218 patent presents some defensible claims, but strategic patent prosecution and potential future amendments should account for existing prior art. Periodic review of related filings and vigilance in monitoring infringement are essential.


Conclusion

The '218 patent reflects a meaningful advancement within its technical domain. Its claims, while broad and innovative, warrant ongoing scrutiny for potential vulnerabilities rooted in prior art. Strategic leveraging of its scope, coupled with proactive patent portfolio management, can maximize its value. Nonetheless, careful monitoring of the evolving patent landscape is necessary to maintain competitive advantage and defend against invalidity or design-around efforts.


Key Takeaways

  • The '218 patent's independent claims define a potentially robust inventive concept but require continuous monitoring for prior art disclosures that might challenge validity.
  • Claimed features should balance breadth to prevent easy design-arounds with specificity to ensure enforceability.
  • The existing patent landscape contains prior art disclosures that could impact the patent's strength; proactive prosecution strategies are essential.
  • Licensing efforts should focus on demonstrating the patent’s unique features and competitive advantage, reinforcing its market position.
  • Ongoing vigilance is necessary to adapt to patent challenges, competitor filings, and technological advancements.

FAQs

1. Can the '218 patent be challenged or invalidated?
Yes, it can be challenged based on prior art disclosures that anticipate or render the claims obvious. Strategic patent drafting minimizes such risks, but vigilance remains essential.

2. How does the scope of the claims affect licensing opportunities?
Broader claims typically facilitate wider licensing, but they risk invalidation if overly encompassing. Narrower claims may limit licensing revenue but offer stronger enforceability.

3. What are common grounds for patent invalidation in this context?
Anticipation by prior art, obviousness combining existing references, lack of novelty, or insufficient disclosure are typical grounds.

4. How does the patent landscape influence future innovation?
A dense patent landscape can incentivize innovation through competing rights but may also create freedom-to-operate limitations if overlapping patents are enforced aggressively.

5. Should patent claims be amended post-grant?
Amendments are possible under post-grant procedures (e.g., ex parte reexamination), allowing patentees to strengthen claims or clarify scope in response to challenges.


Sources:

[1] USPTO Patent Database, Patent No. 10,544,218
[2] Prior art references and filings
[3] Patent prosecution history and related legal documents
[4] Industry analysis reports
[5] Scientific publications and disclosures relevant to the patent subject matter

More… ↓

⤷  Get Started Free

Details for Patent 10,544,218

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Get Started Free 2036-11-11
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 ⤷  Get Started Free 2036-11-11
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 ⤷  Get Started Free 2036-11-11
Eli Lilly And Company ERBITUX cetuximab Injection 125084 February 12, 2004 ⤷  Get Started Free 2036-11-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.